Logo image of NBIX

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Overview

USA - NASDAQ:NBIX - US64125C1099 - Common Stock

143.76 USD
+2.29 (+1.62%)
Last: 10/23/2025, 2:30:00 PM

NBIX Key Statistics, Chart & Performance

Key Statistics
Market Cap14.26B
Revenue(TTM)2.51B
Net Income(TTM)348.30M
Shares99.18M
Float97.44M
52 Week High154.61
52 Week Low84.23
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)3.38
PE42.53
Fwd PE21.73
Earnings (Next)10-28 2025-10-28/bmo
IPO1996-05-23
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


NBIX short term performance overview.The bars show the price performance of NBIX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

NBIX long term performance overview.The bars show the price performance of NBIX in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20 25

The current stock price of NBIX is 143.76 USD. In the past month the price decreased by -3.55%. In the past year, price increased by 21.87%.

NEUROCRINE BIOSCIENCES INC / NBIX Daily stock chart

NBIX Latest News, Press Relases and Analysis

NBIX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.62 404.42B
AMGN AMGEN INC 13.43 157.71B
GILD GILEAD SCIENCES INC 15.45 148.38B
VRTX VERTEX PHARMACEUTICALS INC 25.04 108.74B
REGN REGENERON PHARMACEUTICALS 12.55 60.71B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.82B
ARGX ARGENX SE - ADR 88.81 50.36B
ONC BEONE MEDICINES LTD-ADR 5.02 34.10B
INSM INSMED INC N/A 33.37B
NTRA NATERA INC N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.95B
BIIB BIOGEN INC 9.3 21.82B

About NBIX

Company Profile

NBIX logo image Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Company Info

NEUROCRINE BIOSCIENCES INC

6027 Edgewood Bend Court

San Diego CALIFORNIA 92130 US

CEO: Kevin C. Gorman

Employees: 1800

NBIX Company Website

NBIX Investor Relations

Phone: 18586177600

NEUROCRINE BIOSCIENCES INC / NBIX FAQ

What is the stock price of NEUROCRINE BIOSCIENCES INC today?

The current stock price of NBIX is 143.76 USD. The price increased by 1.62% in the last trading session.


What is the ticker symbol for NEUROCRINE BIOSCIENCES INC stock?

The exchange symbol of NEUROCRINE BIOSCIENCES INC is NBIX and it is listed on the Nasdaq exchange.


On which exchange is NBIX stock listed?

NBIX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NEUROCRINE BIOSCIENCES INC stock?

34 analysts have analysed NBIX and the average price target is 169.88 USD. This implies a price increase of 18.17% is expected in the next year compared to the current price of 143.76. Check the NEUROCRINE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NEUROCRINE BIOSCIENCES INC worth?

NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of 14.26B USD. This makes NBIX a Large Cap stock.


How many employees does NEUROCRINE BIOSCIENCES INC have?

NEUROCRINE BIOSCIENCES INC (NBIX) currently has 1800 employees.


What are the support and resistance levels for NEUROCRINE BIOSCIENCES INC (NBIX) stock?

NEUROCRINE BIOSCIENCES INC (NBIX) has a support level at 139.7 and a resistance level at 144.17. Check the full technical report for a detailed analysis of NBIX support and resistance levels.


Is NEUROCRINE BIOSCIENCES INC (NBIX) expected to grow?

The Revenue of NEUROCRINE BIOSCIENCES INC (NBIX) is expected to grow by 18.64% in the next year. Check the estimates tab for more information on the NBIX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NEUROCRINE BIOSCIENCES INC (NBIX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NEUROCRINE BIOSCIENCES INC (NBIX) stock pay dividends?

NBIX does not pay a dividend.


When does NEUROCRINE BIOSCIENCES INC (NBIX) report earnings?

NEUROCRINE BIOSCIENCES INC (NBIX) will report earnings on 2025-10-28, before the market open.


What is the Price/Earnings (PE) ratio of NEUROCRINE BIOSCIENCES INC (NBIX)?

The PE ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 42.53. This is based on the reported non-GAAP earnings per share of 3.38 and the current share price of 143.76 USD. Check the full fundamental report for a full analysis of the valuation metrics for NBIX.


What is the Short Interest ratio of NEUROCRINE BIOSCIENCES INC (NBIX) stock?

The outstanding short interest for NEUROCRINE BIOSCIENCES INC (NBIX) is 4.23% of its float. Check the ownership tab for more information on the NBIX short interest.


NBIX Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to NBIX. When comparing the yearly performance of all stocks, NBIX is one of the better performing stocks in the market, outperforming 77.63% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NBIX Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to NBIX. Both the health and profitability get an excellent rating, making NBIX a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NBIX Financial Highlights

Over the last trailing twelve months NBIX reported a non-GAAP Earnings per Share(EPS) of 3.38. The EPS increased by 2.11% compared to the year before.


Industry RankSector Rank
PM (TTM) 13.88%
ROA 8.95%
ROE 12.93%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%68.25%
Sales Q2Q%16.49%
EPS 1Y (TTM)2.11%
Revenue 1Y (TTM)18.42%

NBIX Forecast & Estimates

34 analysts have analysed NBIX and the average price target is 169.88 USD. This implies a price increase of 18.17% is expected in the next year compared to the current price of 143.76.

For the next year, analysts expect an EPS growth of 37.76% and a revenue growth 18.64% for NBIX


Analysts
Analysts83.53
Price Target169.88 (18.17%)
EPS Next Y37.76%
Revenue Next Year18.64%

NBIX Ownership

Ownership
Inst Owners100.77%
Ins Owners1.01%
Short Float %4.23%
Short Ratio4.6